These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 10190791

  • 1. Paclitaxel in the treatment of hormone-refractory prostate cancer.
    Smith DC, Pienta KJ.
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):109-11. PubMed ID: 10190791
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ, Smith DC.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC, Chay CH, Dunn RL, Fardig J, Esper P, Olson K, Pienta KJ.
    Cancer; 2003 Jul 15; 98(2):269-76. PubMed ID: 12872344
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
    Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, McAleer C.
    Semin Oncol; 1995 Oct 15; 22(5 Suppl 12):41-5. PubMed ID: 7481860
    [Abstract] [Full Text] [Related]

  • 7. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
    Mackler NJ, Pienta KJ, Dunn RL, Cooney KA, Redman BG, Olson KB, Fardig JE, Smith DC.
    Clin Genitourin Cancer; 2007 Jun 15; 5(5):318-22. PubMed ID: 17645828
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Paclitaxel-based treatment of lymphoma.
    Younes A.
    Semin Oncol; 1999 Feb 15; 26(1 Suppl 2):123-8. PubMed ID: 10190794
    [Abstract] [Full Text] [Related]

  • 13. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ, Dunn RL, Hellerstedt B, Cooney KA, Fardig J, Olson K, Pienta KJ, Smith DC.
    Cancer; 2006 Jun 15; 106(12):2617-23. PubMed ID: 16691618
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer.
    Hainsworth JD, Greco FA.
    Semin Oncol; 1999 Feb 15; 26(1 Suppl 2):60-6. PubMed ID: 10190785
    [Abstract] [Full Text] [Related]

  • 18. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
    Berruti A, Fara E, Tucci M, Tarabuzzi R, Mosca A, Terrone C, Gorzegno G, Fasolis G, Tampellini M, Porpiglia F, De Stefanis M, Fontana D, Bertetto O, Dogliotti L, Gruppo Onco-Urologico Piemontese, Rete Oncologica Piemontese.
    Urol Oncol; 2005 Feb 15; 23(1):1-7. PubMed ID: 15885575
    [Abstract] [Full Text] [Related]

  • 19. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE.
    J Natl Cancer Inst; 2007 Nov 07; 99(21):1613-22. PubMed ID: 17971530
    [Abstract] [Full Text] [Related]

  • 20. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R, Kerlin KJ, Michalski JM, Sandler HM, Radiation Therapy Oncology Group Trial 9902.
    Int J Radiat Oncol Biol Phys; 2009 Mar 01; 73(3):672-8. PubMed ID: 18990504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.